uniQure N.V. Foreign Currency Transaction Gain (Loss), before Tax
uniQure N.V. (QURE) reported Foreign Currency Transaction Gain (Loss), before Tax of -$2.29 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-05-05
- uniQure N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$2.29M, a 131.99% decline year-over-year.
- uniQure N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $749.00K.
- uniQure N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$428.00K, a 105.66% decline year-over-year.
- uniQure N.V. foreign currency transaction gain (loss), before tax for the quarter ending 2025-06-30 was $18.64M.
- uniQure N.V. foreign currency transaction gain (loss), before tax for fiscal 2025 was $26.13M.
- uniQure N.V. foreign currency transaction gain (loss), before tax for fiscal 2024 was -$10.51M.
- uniQure N.V. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$1.69M, a 107.28% decline from fiscal 2022.
- uniQure N.V. foreign currency transaction gain (loss), before tax for fiscal 2022 was $23.23M, a 21.66% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$2.29M 10-Q · filed 2026-05-05 | -$1.54M derived: sum of 2 quarters · filed 2026-05-05 | -$1.97M derived: sum of 3 quarters · filed 2026-05-05 | $16.66M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $749.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $321.00K derived: sum of 2 quarters · filed 2026-03-02 | $18.96M derived: sum of 3 quarters · filed 2026-03-02 | $26.13M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$428.00K 10-Q · filed 2025-11-10 | $18.21M derived: sum of 2 quarters · filed 2025-11-10 | $25.38M 10-Q · filed 2025-11-10 | $9.45M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $18.64M 10-Q · filed 2025-07-29 | $25.81M 10-Q · filed 2025-07-29 | $9.87M derived: sum of 3 quarters · filed 2026-05-05 | $17.44M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $7.17M 10-Q · filed 2026-05-05 | -$8.77M derived: sum of 2 quarters · filed 2026-05-05 | -$1.20M derived: sum of 3 quarters · filed 2026-05-05 | -$2.19M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$15.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$8.37M derived: sum of 2 quarters · filed 2026-03-02 | -$9.36M derived: sum of 3 quarters · filed 2026-03-02 | -$10.51M 10-K · filed 2026-03-02 |
| 2024-09-30 | $7.56M 10-Q · filed 2025-11-10 | $6.58M derived: sum of 2 quarters · filed 2025-11-10 | $5.43M 10-Q · filed 2025-11-10 | $5.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$989.00K 10-Q · filed 2025-07-29 | -$2.13M 10-Q · filed 2025-07-29 | -$2.02M derived: sum of 3 quarters · filed 2026-03-02 | -$1.83M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$1.15M 10-Q · filed 2025-05-09 | -$1.03M derived: sum of 2 quarters · filed 2026-03-02 | -$841.00K derived: sum of 3 quarters · filed 2026-03-02 | -$467.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $304.00K derived: sum of 2 quarters · filed 2026-03-02 | $678.00K derived: sum of 3 quarters · filed 2026-03-02 | -$1.69M 10-K · filed 2026-03-02 |
| 2023-09-30 | $186.00K 10-Q · filed 2024-11-05 | $560.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.81M 10-Q · filed 2024-11-05 | -$20.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $374.00K 10-Q · filed 2024-08-01 | -$2.00M 10-Q · filed 2024-08-01 | -$21.09M derived: sum of 3 quarters · filed 2025-02-27 | -$6.73M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$2.37M 10-Q · filed 2024-05-07 | -$21.46M derived: sum of 2 quarters · filed 2025-02-27 | -$7.10M derived: sum of 3 quarters · filed 2025-02-27 | $12.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$19.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.73M derived: sum of 2 quarters · filed 2025-02-27 | $14.67M derived: sum of 3 quarters · filed 2025-02-27 | $23.23M 10-K · filed 2025-02-27 |
| 2022-09-30 | $14.36M 10-Q · filed 2023-11-07 | $33.76M derived: sum of 2 quarters · filed 2023-11-07 | $42.33M 10-Q · filed 2023-11-07 | $50.34M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $19.40M 10-Q · filed 2023-08-01 | $27.97M 10-Q · filed 2023-08-01 | $35.98M derived: sum of 3 quarters · filed 2024-02-28 | $46.42M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $8.57M 10-Q · filed 2023-05-09 | $16.58M derived: sum of 2 quarters · filed 2024-02-28 | $27.02M derived: sum of 3 quarters · filed 2024-02-28 | $33.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $8.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $18.45M derived: sum of 2 quarters · filed 2024-02-28 | $25.03M derived: sum of 3 quarters · filed 2024-02-28 | $29.66M 10-K · filed 2024-02-28 |
| 2021-09-30 | $10.44M 10-Q · filed 2022-11-02 | $17.02M derived: sum of 2 quarters · filed 2022-11-02 | $21.64M 10-Q · filed 2022-11-02 | $15.76M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $6.58M 10-Q · filed 2022-08-08 | $11.21M 10-Q · filed 2022-08-08 | $5.32M derived: sum of 3 quarters · filed 2023-02-27 | -$3.36M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $4.63M 10-Q · filed 2022-05-02 | -$1.26M derived: sum of 2 quarters · filed 2023-02-27 | -$9.94M derived: sum of 3 quarters · filed 2023-02-27 | -$13.59M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$14.57M derived: sum of 2 quarters · filed 2023-02-27 | -$18.21M derived: sum of 3 quarters · filed 2023-02-27 | -$13.61M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$8.68M 10-Q · filed 2021-10-25 | -$12.33M derived: sum of 2 quarters · filed 2021-10-25 | -$7.72M 10-Q · filed 2021-10-25 | -$15.05M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$3.65M 10-Q · filed 2021-07-26 | $957.00K 10-Q · filed 2021-07-26 | -$6.37M derived: sum of 3 quarters · filed 2022-02-25 | -$333.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.60M 10-Q · filed 2021-05-10 | -$2.73M derived: sum of 2 quarters · filed 2022-02-25 | $3.31M derived: sum of 3 quarters · filed 2022-02-25 | $2.06M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$7.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$1.29M derived: sum of 2 quarters · filed 2022-02-25 | -$2.54M derived: sum of 3 quarters · filed 2022-02-25 | -$268.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $6.04M 10-Q · filed 2020-10-27 | $4.79M derived: sum of 2 quarters · filed 2020-10-27 | $7.06M 10-Q · filed 2020-10-27 | $8.56M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$1.25M 10-Q · filed 2020-07-30 | $1.02M 10-Q · filed 2020-07-30 | $2.52M derived: sum of 3 quarters · filed 2021-03-01 | $2.97M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $2.27M 10-Q · filed 2020-04-29 | $3.77M derived: sum of 2 quarters · filed 2021-03-01 | $4.22M derived: sum of 3 quarters · filed 2021-03-01 | $6.48M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.95M derived: sum of 2 quarters · filed 2021-03-01 | $4.20M derived: sum of 3 quarters · filed 2021-03-01 | $4.38M 10-K · filed 2021-03-01 |
| 2018-09-30 | $455.00K 10-Q · filed 2019-10-28 | $2.71M derived: sum of 2 quarters · filed 2019-10-28 | $2.89M 10-Q · filed 2019-10-28 | $1.17M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $2.25M 10-Q · filed 2019-07-29 | $2.43M 10-Q · filed 2019-07-29 | $712.00K derived: sum of 3 quarters · filed 2020-03-02 | $31.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $178.00K 10-Q · filed 2019-04-29 | -$1.54M derived: sum of 2 quarters · filed 2020-03-02 | -$2.22M derived: sum of 3 quarters · filed 2020-03-02 | -$3.29M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | -$1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$2.40M derived: sum of 2 quarters · filed 2020-03-02 | -$3.47M derived: sum of 3 quarters · filed 2020-03-02 | -$3.57M 10-K · filed 2020-03-02 |
| 2017-09-30 | -$681.00K 10-Q · filed 2018-11-06 | -$1.75M derived: sum of 2 quarters · filed 2018-11-06 | -$1.84M 10-Q · filed 2018-11-06 | $953.00K derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | -$1.07M 10-Q · filed 2018-08-08 | -$1.16M 10-Q · filed 2018-08-08 | $1.63M derived: sum of 3 quarters · filed 2019-02-28 | $1.14M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | -$93.00K 10-Q · filed 2018-04-30 | $2.71M derived: sum of 2 quarters · filed 2019-02-28 | $2.21M derived: sum of 3 quarters · filed 2019-02-28 | $3.13M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $2.30M derived: sum of 2 quarters · filed 2019-02-28 | $3.22M derived: sum of 3 quarters · filed 2019-02-28 | $1.03M 10-K · filed 2019-02-28 |
| 2016-09-30 | -$496.00K 10-Q · filed 2017-11-01 | $424.00K derived: sum of 2 quarters · filed 2017-11-01 | -$1.76M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $920.00K 10-Q · filed 2017-08-08 | -$1.27M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | -$2.19M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | -$2.50M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $5.15M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |